Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ipsen Pharma

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
From Ipsen Pharma
Via GlobeNewswire
Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs
From Ipsen Pharma
Via GlobeNewswire
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
From Ipsen Pharma
Via GlobeNewswire
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
From Ipsen Pharma
Via GlobeNewswire
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
From Ipsen Pharma
Via GlobeNewswire
Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs
From Ipsen Pharma
Via GlobeNewswire
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
From Ipsen Pharma
Via GlobeNewswire
Ipsen presents strong full-year 2022 results and guidance for 2023
From Ipsen Pharma
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.